Here, we characterized 2 immuno-PET antibodies targeting the human uPAR (huPAR) and murine uPAR (muPAR) forms from commercial sources to address preclinical questions in aging, pancreatic cancer, and chemotherapy-induced senescence. This evidence concerns the gene PLAUR and pancreatic neoplasm.